Perspective Therapeutics, Inc. (NYSE:CATX) Receives Consensus Rating of “Buy” from Analysts

Perspective Therapeutics, Inc. (NYSE:CATXGet Free Report) has been assigned a consensus recommendation of “Buy” from the six analysts that are presently covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $1.90.

Several equities analysts recently issued reports on CATX shares. Lifesci Capital reissued an “outperform” rating on shares of Perspective Therapeutics in a report on Monday, May 6th. B. Riley increased their price objective on shares of Perspective Therapeutics from $1.20 to $1.70 and gave the company a “buy” rating in a report on Tuesday, April 9th. Oppenheimer reaffirmed an “outperform” rating and set a $1.50 price objective (up from $1.20) on shares of Perspective Therapeutics in a research note on Monday, April 1st. Cantor Fitzgerald started coverage on Perspective Therapeutics in a research report on Thursday, May 9th. They set an “overweight” rating for the company. Finally, Royal Bank of Canada started coverage on shares of Perspective Therapeutics in a research report on Tuesday, May 14th. They issued an “outperform” rating and a $3.00 price target on the stock.

Get Our Latest Research Report on Perspective Therapeutics

Perspective Therapeutics Stock Performance

NYSE CATX opened at $1.33 on Friday. Perspective Therapeutics has a 1-year low of $0.21 and a 1-year high of $1.91. The company has a debt-to-equity ratio of 0.01, a current ratio of 12.98 and a quick ratio of 12.98.

Perspective Therapeutics shares are scheduled to reverse split on Monday, June 17th. The 1-10 reverse split was announced on Monday, June 17th. The number of shares owned by shareholders will be adjusted after the market closes on Monday, June 17th.

Perspective Therapeutics (NYSE:CATXGet Free Report) last announced its quarterly earnings results on Wednesday, May 15th. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. Perspective Therapeutics had a negative return on equity of 46.38% and a negative net margin of 302.70%. The firm had revenue of $0.33 million for the quarter. On average, equities analysts forecast that Perspective Therapeutics will post -0.11 EPS for the current fiscal year.

Insiders Place Their Bets

In other Perspective Therapeutics news, CFO Jonathan Robert Hunt acquired 25,006 shares of the business’s stock in a transaction dated Friday, May 31st. The shares were acquired at an average price of $1.40 per share, for a total transaction of $35,008.40. Following the acquisition, the chief financial officer now directly owns 341,716 shares of the company’s stock, valued at approximately $478,402.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO Jonathan Robert Hunt acquired 25,006 shares of the company’s stock in a transaction that occurred on Friday, May 31st. The shares were acquired at an average cost of $1.40 per share, for a total transaction of $35,008.40. Following the completion of the acquisition, the chief financial officer now directly owns 341,716 shares in the company, valued at approximately $478,402.40. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Lori A. Woods bought 34,246 shares of Perspective Therapeutics stock in a transaction that occurred on Monday, June 3rd. The stock was bought at an average cost of $1.46 per share, with a total value of $49,999.16. Following the completion of the purchase, the director now owns 1,553,984 shares in the company, valued at approximately $2,268,816.64. The disclosure for this purchase can be found here. Insiders acquired 144,283 shares of company stock worth $200,849 over the last ninety days. 3.52% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Perspective Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. ZWJ Investment Counsel Inc. bought a new stake in Perspective Therapeutics during the 1st quarter worth about $26,000. Simplicity Wealth LLC bought a new stake in Perspective Therapeutics during the first quarter worth about $40,000. Bleakley Financial Group LLC bought a new stake in Perspective Therapeutics during the first quarter worth about $40,000. RIA Advisory Group LLC boosted its position in Perspective Therapeutics by 1,313.4% during the first quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock valued at $127,000 after purchasing an additional 99,293 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in Perspective Therapeutics in the first quarter valued at approximately $138,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

(Get Free Report

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

Recommended Stories

Analyst Recommendations for Perspective Therapeutics (NYSE:CATX)

Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.